Johnson & Johnson (J&J) has announced that it will increase its presence in North Carolina with a 160,000+ square-foot dedicated manufacturing facility at Fujifilm Biotechnologies’ new biopharmaceutical manufacturing site in Holly Springs, North Carolina. The $2-billion commitment to Fujifilm over the next 10 years will expand the J&J’s US manufacturing capacity and create approximately 120 new jobs in North Carolina. 

In the coming months (as reported on August 21, 2025), J&J also says it intends to share plans for additional advanced manufacturing facilities in the US as well as expand current US sites to enable the company to manufacture the vast majority of its medicines in the US for US patients. 

J&J says it has more manufacturing in the US than elsewhere, and the additional $2 billion being invested in North Carolina continues other US investments announced by the company. In March (March 2025), J&J announced manufacturing, research and development, and technology investments of more than $55 billion in the US over the next four years, which includes a $2-billion investment in a 500,000-square-foot biologics manufacturing facility in Wilson, North Carolina, which the company started construction of in March (March 2025). In addition, the multi-year investment includes: (1) three new advanced manufacturing facilities and the expansion of several existing sites across the company’s Innovative Medicine and MedTech businesses; (2) investments in R&D infrastructure for developing therapeutics in areas such as oncology, neuroscience, immunology, and cardiovascular disease as well as investments in robotic surgery; and (3) increased technology investments in drug-discovery and development activities, workforce training, and business operations. 

Source: Johnson & Johnson